Clinical Trial Update: Safety Study of Atomoxetine and Cerebrovascular Outcomes

View source ↗

Summary

This trial update reports the completed safety study of atomoxetine examining cerebrovascular outcomes in ADHD patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Stroke
• Transient Ischemic Attack

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cerebrovascular Accident, Transient Ischemic Attack | Status: COMPLETED